Midatech (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology, today confirms the appointment of Dr Craig Cook as its Chief Executive Officer and Board Director, and the resignation of Dr Jim Phillips, further to the announcement on 15 March 2018.
Dr Craig Richard Cook, aged 51 is, or has been in the previous five years, a director or partner of the following companies:
|Current appointments||Past appointments|
|2X1Y Ltd||Sedation Solutions Limited|
|Swisscare Health Limited|
|Winstead Assets Ltd|
Craig Cook has a beneficial interest in 6,000 ordinary shares in the capital of Midatech, which represents 0.01% of the Company’s issued share capital. Also Craig Cook has options over 961,000 ordinary shares, which represents 1.57% of the Company’s issued share capital.
There are no arrangements or understanding pursuant to which Craig Cook was appointed as Chief Executive Officer or a Director.
Save as disclosed in this announcement, there are no further disclosures to be made in relation to Rule 17 of paragraph (g) of Schedule Two of the AIM Rules for Companies in respect of Craig Cook’s appointment.